| BWAY |
BrainsWay Ltd. |
72%
|
oodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We operate as a single reporting unit and test goodwill… |
| BWAY |
BrainsWay Ltd. |
72%
|
Reciprocal relationship from BWAY graph: Reciprocal relationship from NCEL graph: Reciprocal relationship from BWAY graph: Reciprocal relationship from NCEL graph: oodwill Goodwill represents the exc… |
| ELDN |
Eledon Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from ELDN graph: Reciprocal relationship from NCEL graph: gulatory authority approvals to do so. The facilities and quality systems of some or all of its collaborators and thi… |
| ELDN |
Eledon Pharmaceuticals, Inc. |
72%
|
gulatory authority approvals to do so. The facilities and quality systems of some or all of its collaborators and third-party contractors must pass a pre-approval inspection for compliance with the a… |
| INCR |
InterCure Ltd. |
72%
|
oodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We operate as a single reporting unit and test goodwill… |
| INCR |
InterCure Ltd. |
72%
|
Reciprocal relationship from INCR graph: Reciprocal relationship from NCEL graph: oodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired … |
| SVRE |
SaverOne 2014 Ltd. |
72%
|
oodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We operate as a single reporting unit and test goodwill… |
| SVRE |
SaverOne 2014 Ltd. |
72%
|
Reciprocal relationship from SVRE graph: Reciprocal relationship from NCEL graph: Reciprocal relationship from SVRE graph: Reciprocal relationship from NCEL graph: Reciprocal relationship from SVRE g… |
| XTLB |
XTL Biopharmaceuticals Ltd. |
72%
|
Reciprocal relationship from XTLB graph: Reciprocal relationship from NCEL graph: oodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired … |
| XTLB |
XTL Biopharmaceuticals Ltd. |
72%
|
oodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We operate as a single reporting unit and test goodwill… |
| AEXON-LABS-INC |
AEXON-LABS-INC |
62%
|
2), as well as in the development of the NCEL-101 product in support of the Pre-IND submission together with iTolerance, for continuing the development procedures of the innovative diabetes treatment… |
| ALS-GRANTED-NEWCELX-LTD |
ALS-GRANTED-NEWCELX-LTD |
62%
|
2), as well as in the development of the NCEL-101 product in support of the Pre-IND submission together with iTolerance, for continuing the development procedures of the innovative diabetes treatment… |
| ALTHOUGH-NEWCELX-LTD |
ALTHOUGH-NEWCELX-LTD |
62%
|
placement. NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science. including phase IIa clinical trial for… |
| BCLI |
Brainstorm Cell Therapeutics Inc. |
62%
|
Reciprocal relationship from BCLI graph: Reciprocal relationship from NCEL graph: ens the development time nor regulatory review time of a drug nor does it increase the likelihood for any approval in… |
| BRAINSTORM-CELL-THERAPEUTICS-INC |
BRAINSTORM-CELL-THERAPEUTICS-INC |
62%
|
ens the development time nor regulatory review time of a drug nor does it increase the likelihood for any approval in the regulatory review process. Sponsors requesting designation of the same drug f… |
| BUBBLES-INTERGROUP-LTD |
BUBBLES-INTERGROUP-LTD |
62%
|
oodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We operate as a single reporting unit and test goodwill… |
| CELLECT-BIOTECHNOLOGY-LTD |
CELLECT-BIOTECHNOLOGY-LTD |
62%
|
oodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We operate as a single reporting unit and test goodwill… |
| DEVELOPMENT-CO-LTD |
DEVELOPMENT-CO-LTD |
62%
|
2), as well as in the development of the NCEL-101 product in support of the Pre-IND submission together with iTolerance, for continuing the development procedures of the innovative diabetes treatment… |
| EMERGING-GROWTH-COMPANY |
EMERGING-GROWTH-COMPANY |
62%
|
nted to $ 296 thousand. These costs are recorded within current assets on the consolidated balance sheet. Upon the future issuance of shares under the ELOC facility, these costs will be reclassified … |
| GRANTED-NEWCELX-LTD |
GRANTED-NEWCELX-LTD |
62%
|
2), as well as in the development of the NCEL-101 product in support of the Pre-IND submission together with iTolerance, for continuing the development procedures of the innovative diabetes treatment… |
| MERGER-NLS-PHARMACEUTICS-LTD |
MERGER-NLS-PHARMACEUTICS-LTD |
62%
|
2), as well as in the development of the NCEL-101 product in support of the Pre-IND submission together with iTolerance, for continuing the development procedures of the innovative diabetes treatment… |
| MER-TELEMANAGEMENT-SOLUTIONS-LTD |
MER-TELEMANAGEMENT-SOLUTIONS-LTD |
62%
|
oodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We operate as a single reporting unit and test goodwill… |
| NLS-PHARMACEUTICS-LTD |
NLS-PHARMACEUTICS-LTD |
62%
|
27, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-11. On October 30, 2025 (the “Closing Date”… |
| SYDNEY-CELL-THERAPY-FOUNDATION-PTY-LIMITED |
SYDNEY-CELL-THERAPY-FOUNDATION-PTY-LIMITED |
62%
|
ens the development time nor regulatory review time of a drug nor does it increase the likelihood for any approval in the regulatory review process. Sponsors requesting designation of the same drug f… |
| TEL-AVIV-UNIVERSITY-LTD |
TEL-AVIV-UNIVERSITY-LTD |
62%
|
any has not yet made any payments in respect of the milestones. F- 29 NEWCELX LTD. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS NOTE 10: – CONTINGENT LIABILITIES AND COMMITMENTS (Cont.) D. On Novem… |
| VERTEX-THERAPEUTICS-CENTURY-THERAPEUTICS-SANA-BI |
VERTEX-THERAPEUTICS-CENTURY-THERAPEUTICS-SANA-BI |
62%
|
ens the development time nor regulatory review time of a drug nor does it increase the likelihood for any approval in the regulatory review process. Sponsors requesting designation of the same drug f… |
| VSTOCK-TRANSFER-LLC |
VSTOCK-TRANSFER-LLC |
62%
|
placement. NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science. including phase IIa clinical trial for… |
